The rising popularity of GLP-1 medications for weight loss is notable, yet a recent analysis from the Kaiser Family Foundation (KFF) reveals that less than 20% of large employers are providing coverage for these expensive prescriptions. GLP-1 drugs, which include brand names like Ozempic and Wegovy, were initially developed to manage blood sugar levels in...
Premium Membership Required
You must be a Premium member to access this content.
Already a member? Log in here
